(Q33383818)

English

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

author name string

Robert J Amato

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jaroslaw Jac

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sarah Giessinger

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Somyata Saxena

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James P Willis

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2438-2446

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

21 January 2018

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting von Hippel-Lindau pathway in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of VHL gene mutation in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

mTOR, translation initiation and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Sirolimus-associated pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24280

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24280

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33383818&oldid=1536493103"